SwePub
Sök i SwePub databas

  Utökad sökning

Booleska operatorer måste skrivas med VERSALER

AND är defaultoperator och kan utelämnas

Träfflista för sökning "AMNE:(MEDICAL AND HEALTH SCIENCES Clinical Medicine Cancer and Oncology) srt2:(2010-2014)"

Sökning: AMNE:(MEDICAL AND HEALTH SCIENCES Clinical Medicine Cancer and Oncology) > (2010-2014)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
11.
  • Johansson, Bengt, 1958- (författare)
  • Long-term outcome research on PDR brachytherapy with focus on breast, base of tongue and lip cancer
  • 2010
  • Doktorsavhandling (övrigt vetenskapligt)abstract
    • <p>Brachytherapy (BT) with continuous low dose rate (LDR) has been used for 100 years and is considered as the radiotherapy method able to deliver a dose in the shortest time with high efficacy and low risk of side effects. The drawbacks are need for patient isolation and radiation exposure of the staff during the treatment.</p> <p>Brenner and Hall published the radiobiology concept for pulsed dose rate (PDR) in 1991.  Short (10-20 minutes), hourly pulses of high dose rate (HDR) given to the same dose, with same overall treatment time will virtually simulate continuous LDR. At the same time new afterloading machine technology became available, where a single millimetre sized radiation <sup>192</sup>Iridium source sequentially moves through the applicator in small individually timed steps. The advantages are that the radiation dose can be optimized along the applicator and with no radiation exposure of the staff and no need for patient isolation more than during the pulse. This work deals with four different aspects of PDR BT</p> <p>An experimental comparison of measured absorbed doses outside a left sided breast target on a body equivalent Alderson phantom was made.  Five external beam radiotherapy (EBRT) whole breast treatments to 50 Gy versus five accelerated partial breast irradiations (APBI) by PDR BT to 50 Gy were studied. The absorbed doses were measured in 67 different positions inside the body phantom by thermoluminescence dosimeters. The result shows that dose points distant to the left breast will have 1-1.4 % of the prescribed dose with no difference between EBRT and PDR BT. Organs at risk in short distance (&lt;5 cm) to the target (such as parts of the left lung, heart muscle and the right breast) will have significantly less dose by PDR BT. In conclusion PDR BT has dosimetric advantages close to the target compared to EBRT and cannot do more damage to remote organs.</p> <p>PDR APBI as the adjuvant RT treatment to breast conserving surgery after early breast cancer was studied. Between 1994-2004 we treated 50 women and 51 breasts. The median age of the population was 53 (40-72) years. The cases were radically resected, unifocal T1-2N0-1M0 tumours. PDR BT was given to a dose of 50 Gy for 5 days directed to the operated sector of the breast. The median treated volume was 160 cm<sup>3</sup>, constituting in median 31 % of the breast volume. The treatment is called accelerated because total treatment time is 5 days compared to 5 weeks for EBRT. After a median follow-up of 130 months (&gt;10 years) we noted 5 (10 %) local recurrences in the treated breast. Four of these recurrences were outside the treated volume. Three women (6 %) developed cancers in the other breast. Early side effects were mild and less than with EBRT. As late side effects we found mild to moderate local fibroses in the treated volume. A cosmetic evaluation was done by both the patient and a nurse and was found to be lower than in other published data (56 % = good to excellent). The 10 years local failure rate is similar to the result from a large Swedish randomized study on whole breast radiotherapy to 50 Gy. The study indicates that PDR BT is highly effective.</p> <p>A combination of EBRT (40.8 Gy) and PDR boost (35 Gy) to T1-4N0-3M0, base of tongue (BOT) cancer, treated during 1994-2007 was analyzed. The study is the first with PDR and second largest with BT worldwide. A number of 83 patients with a median age of 60 (38-82) years were included. BT was given to a mean volume of 58 ccm 2 days after the neck dissection. Median follow-up was 54 months. At 5 years we found 89 % local tumour control, 95 % neck control, 80 % disease free survival and an overall survival of 65 %. Late side effects were 13 % minor transient soft tissue necrosis and 12 % long lasting or permanent soft tissue- or osteoradio-necrosis. The results are among the best published worldwide. An extensive quality of life analysis was done on 45 patients at last follow-up and showed limited, persistent xerostomia and dysphagia. The global quality of life was rated good in 75 % of the patients.</p> <p>The last study presented was PDR mono-brachytherapy (55-60 Gy) to cancer of the lip (T1-3N0M0). The study included 43 patients with a median age of 74 (37-92) years. The treatment time was 5.5-6 days and the mean treated volume was 15 ccm. The median follow-up time was 54 (1-158) months. Five year Kaplan-Meier data showed, local control 94 %, disease free survival 86 % and overall survival 59 %. An early side effect was a strong radiation mucositis and dermatitis, which healed in 1 month. Late side effects were uncommon and the cosmetic appearance and the lip function were found to be normal. Our data in total and per T-stage was compared to a European survey from 1993 on 2794 patients treated by LDR BT. The results are similar and are a strong indication of equal efficacy between PDR and LDR.</p>
  •  
12.
  • Leja, Justyna, et al. (författare)
  • Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells
  • 2011
  • Ingår i: Gene Therapy. - 0969-7128 .- 1476-5462. ; 18:11, s. 1052-1062
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>We have previously described the oncolytic adenovirus, Ad(CgA-E1A-miR122), herein denoted Ad5(CgA-E1A-miR122) that selectively replicates in and kills neuroendocrine cells, including freshly isolated midgut carcinoid cells from liver metastases. Ad5(CgA-E1A-miR122) is based on human adenovirus serotype 5 (Ad5) and infects target cells by binding to the coxsackie-adenovirus receptor (CAR) and integrins on the cell surface. Some neuroendocrine tumor (NET) and neuroblastoma cells express low levels of CAR and are therefore poorly transduced by Ad5. However, they often express high levels of somatostatin receptors (SSTRs). Therefore, we introduced cyclic peptides, which contain four amino acids (FWKT) and mimic the binding site for SSTRs in the virus fiber knob. We show that FWKT-modified Ad5 binds to SSTR<sub>2</sub> on NET cells and transduces midgut carcinoid cells from liver metastases about 3-4 times better than non-modified Ad5 while it transduces normal hepatocytes at about 50% of Ad5. Moreover, FWKT-modified Ad5 overcomes neutralization in an <em>ex vivo</em> human blood loop model to greater extent than Ad5, indicating that fiber knob modification may prolong the systematic circulation time. We conclude that modification of adenovirus with the FWKT motif may be beneficial for NET therapy.</p>
  •  
13.
  • Hofmarcher, Thomas, et al. (författare)
  • Access to high-quality oncology care across Europe
  • 2014
  • Rapport (övrigt vetenskapligt)abstract
    • Oncology care in Europe is facing challenging circumstances. The report aims to derive evidence-based policy recommendations on how to optimize access to oncology care and how to achieve a high-quality standard that is both achievable and sustainable. The report looks at the full cancer patient pathway encompassing primary prevention, screening, diagnostics and treatment. Special emphasis is placed on access to effective screening programs as well as on access to innovative drug treatments. Barriers that prevent access to effective oncology care are identified and determinants of a high-quality standard in care established. The analysis focuses on three common cancer types - colorectal, lung and prostate cancer - and four EU member states - France, Germany, Poland and Sweden. The health-economic burden of cancer is reviewed and countries’ performance on the established access and quality principles assessed and compared. This report was commissioned and funded by Janssen Pharmaceutica NV and based on independent research delivered by IHE. Janssen has had no influence or editorial control over the content of this report, and the views and opinions of the authors are not necessarily those of Janssen.
14.
  •  
15.
  • Lövgren, Malin, et al. (författare)
  • Clock time and embodied time experienced by patients with inoperable lung cancer
  • 2010
  • Ingår i: Cancer Nursing. - Lippincott Williams & Wilkins. - 0162-220X .- 1538-9804. ; 33:1, s. 55-63
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>In this study, we explore how patients with inoperable lung cancer (LC) discuss their experiences of time, based on content analysis of open interviews with 35 patients 1 year after diagnosis, using Davies' distinction between "clock time" and "embodied time" as sensitizing concepts. Two interrelated themes were derived: (1) aspects related to the healthcare system, with 3 subthemes: waiting times in the healthcare system, limited time for patient-professional contact, and limited time for coordination of services, and (2) existential aspects, with subthemes: the future with LC and managing an uncertain and finite life with LC. Time could be experienced as problematic for these patients, when limited or lacking or through long periods of waiting, especially when these periods occurred without adequate preparation or information. This contributed to exacerbation of these patients' existing sense of uncertainty, their perception of care as impersonal and insecure, and their need to remain alert and act on their own behalf. Awareness of the seriousness of their disease and the prospect of a limited lifetime was described as increasing uncertainty about dying and fear of certain death. People also described efforts to constructively deal with their situation by reprioritizing their remaining time, having increased appreciation of some aspects of daily life, and living consciously in the present. This analysis suggests a collision between clock time, which steers the healthcare system, and embodied time, as experienced by individuals. Greater attention to psychosocial needs is suggested as one means of positively affecting patients' experiences of time and uncertainty.</p>
  •  
16.
  • Nilsson, Lena Maria, 1965-, et al. (författare)
  • Consumption of filtered and boiled coffee and the risk of incident cancer : a prospective cohort study
  • 2010
  • Ingår i: Cancer Causes and Control. - Springer Netherlands. - 0957-5243 .- 1573-7225. ; 21:10, s. 1533-1544
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Background  Despite potentially relevant chemical differences between filtered and boiled coffee, this study is the first to investigate consumption in relation to the risk of incident cancer.</p><p>Methods  Subjects were from the Västerbotten Intervention Project (64,603 participants, including 3,034 cases), with up to 15 years of follow-up. Hazard ratios (HR) were calculated by multivariate Cox regression.</p><p>Results  No associations were found for all cancer sites combined, or for prostate or colorectal cancer. For breast cancer, boiled coffee ≥4 versus &lt;1 occasions/day was associated with a reduced risk (HR = 0.52, CI = 0.30–0.88, <em>p</em> <sub>trend</sub> = 0.247). An increased risk of premenopausal and a reduced risk of postmenopausal breast cancer were found for both total (HR<sub>premenopausal</sub> = 1.69, CI = 0.96–2.98, <em>p</em> <sub>trend</sub> = 0.015, HR<sub>postmenopausal</sub> = 0.60, CI = 0.39–0.93, <em>p</em> <sub>trend</sub> = 0.006) and filtered coffee (HR<sub>premenopausal</sub> = 1.76, CI = 1.04–3.00, <em>p</em> <sub>trend</sub> = 0.045, HR<sub>postmenopausal</sub> = 0.52, CI = 0.30–0.88, <em>p</em> <sub>trend</sub> = 0.045). Boiled coffee was positively associated with the risk of respiratory tract cancer (HR = 1.81, CI = 1.06–3.08, <em>p</em> <sub>trend</sub> = 0.084), a finding limited to men. Main results for less common cancer types included total coffee in renal cell cancer (HR = 0.30, CI = 0.11–0.79, <em>p</em> <sub>trend</sub> = 0.009) and boiled coffee in pancreas cancer (HR = 2.51 CI = 1.15–5.50, <em>p</em> <sub>trend</sub> = 0.006).</p><p>Conclusion  These findings demonstrate, for the first time, the potential relevance of brewing method in investigations of coffee consumption and cancer risk, but they must be confirmed in future studies.</p>
  •  
17.
  • Borné, Yan, et al. (författare)
  • Cadmium exposure and incidence of diabetes mellitus - results from the malmö diet and cancer study.
  • 2014
  • Ingår i: PLoS ONE. - Public Library of Science. - 1932-6203. ; 9:11
  • Tidskriftsartikel (refereegranskat)abstract
    • Cadmium is a pollutant with multiple adverse health effects: renal dysfunction, osteoporosis and fractures, cancer, and probably cardiovascular disease. Some studies have reported associations between cadmium and impaired fasting glucose and diabetes. However, this relationship is controversial and there is a lack of longitudinal studies.
18.
  •  
19.
  • Hemmingsson, Oskar, 1975-, et al. (författare)
  • ASNA-1 activity modulates sensitivity to cisplatin
  • 2010
  • Ingår i: Cancer Research. - American Association for Cancer Research. - 0008-5472 .- 1538-7445. ; 70:24, s. 10321-10328
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Cancer can be cured by platinum based chemotherapy but resistance is a major cause of treatment failure. Here we present the nematode Caenorhabditis elegans as a model to study interactions between the platinum drug cisplatin and signaling pathways in vivo. Null mutations in a single gene, asna-1, makes worms hypersensitive to cisplatin. The metalloregulated ATPase ASNA-1 promotes insulin secretion and membrane insertion of tail-anchored proteins. Using structural data from ASNA-1 homologs, we identify specific ASNA-1 mutants that are sensitive to cisplatin while still able to promote insulin signaling. Mutational analysis reveals that hypersensitivity of ASNA-1 mutants to cisplatin remains in absence of CEP-1/p53 or apoptosis. Human ASNA1 can substitute for the worm gene, indicating a conserved function. Cisplatin sensitivity is not affected by decreased insulin signaling in wild type nematodes or restored insulin signaling in asna-1 mutants. These findings provide a functional insight into ASNA-1, demonstrate that C. elegans can be used to characterize cisplatin resistance mechanisms and propose that rationally designed drugs against ASNA-1 can sensitize cancer cells to cisplatin.</p>
  •  
20.
  • Campa, Daniele, et al. (författare)
  • Genetic variability of the fatty acid synthase pathway is not associated with prostate cancer risk in the European Prospective Investigation on Cancer (EPIC)
  • 2011
  • Ingår i: European Journal of Cancer. - Elsevier. - 0959-8049 .- 1879-0852. ; 47:3, s. 420-427
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>A western lifestyle, characterised by low rates of energy expenditure and a high-energy diet rich in animal protein, saturated fats and refined carbohydrates, is associated with high incidence of prostate cancer in men. A high-energy nutritional status results in insulin/IGF signalling in cells, which in turn stimulates synthesis of fatty acids. We investigated whether the genetic variability of the genes belonging to the fatty acid synthesis pathway is related to prostate cancer risk in 815 prostate cancer cases and 1266 controls from the European Prospective Investigation on Cancer (EPIC). Using a tagging approach and selecting 252 SNPs in 22 genes, we covered all the common genetic variation of this pathway. None of the SNPs reached statistical significance after adjusting for multiple comparisons. Common SNPs in the fatty acid synthase pathway are not major contributors to prostate cancer risk.</p>
  •  
Skapa referenser, mejla, bekava och länka
Åtkomst
fritt online (710)
Typ av publikation
tidskriftsartikel (3136)
doktorsavhandling (143)
konferensbidrag (124)
forskningsöversikt (121)
bokkapitel (38)
rapport (7)
visa fler...
samlingsverk (redaktörskap) (6)
annan publikation (6)
bok (3)
licentiatavhandling (2)
patent (1)
visa färre...
Typ av innehåll
refereegranskat (3171)
övrigt vetenskapligt (560)
populärvet., debatt m.m. (11)
Författare/redaktör
Riboli, Elio (192)
Overvad, Kim (182)
Tumino, Rosario (177)
Trichopoulou, Antoni ... (173)
Khaw, Kay-Tee (172)
Boeing, Heiner (171)
visa fler...
Kaaks, Rudolf (147)
Bueno-de-Mesquita, H ... (134)
Tjonneland, Anne (132)
Manjer, Jonas, (132)
Palli, Domenico (132)
Jirström, Karin, (120)
Vineis, Paolo (118)
Clavel-Chapelon, Fra ... (114)
Trichopoulos, Dimitr ... (113)
Boutron-Ruault, Mari ... (110)
Panico, Salvatore (108)
Hemminki, Kari, (106)
Peeters, Petra H M (101)
Sanchez, Maria-Jose (98)
Barricarte, Aurelio (97)
Lund, Eiliv (93)
Trichopoulou, A (88)
Overvad, K (86)
Riboli, E (86)
Travis, Ruth C (83)
Dorronsoro, Miren (83)
Wareham, Nick (82)
Weiderpass, Elisabet ... (82)
Steineck, G, (82)
Tjonneland, A (81)
Tumino, R (81)
Romieu, Isabelle (79)
Stattin, Pär, (78)
Hallmans, Göran (78)
Kaaks, R (76)
Jenab, Mazda (76)
Olsson, Håkan, (75)
Lukanova, Annekatrin (75)
Boeing, H (74)
Ardanaz, Eva (72)
Allen, Naomi E. (71)
Lagiou, Pagona (70)
Sacerdote, Carlotta (69)
Forssell-Aronsson, E ... (69)
Steineck, Gunnar, 19 ... (67)
Tjønneland, Anne (65)
Sundquist, Jan, (65)
Weiderpass, E, (63)
Palli, D (63)
visa färre...
Lärosäte
Lunds universitet (1382)
Karolinska Institutet (699)
Umeå universitet (670)
Göteborgs universitet (649)
Uppsala universitet (398)
Örebro universitet (122)
visa fler...
Linköpings universitet (77)
Stockholms universitet (61)
Chalmers tekniska högskola (46)
Kungliga Tekniska Högskolan (22)
Sveriges Lantbruksuniversitet (18)
Högskolan i Skövde (17)
Högskolan i Jönköping (9)
Linnéuniversitetet (8)
Mittuniversitetet (7)
Högskolan i Borås (7)
Högskolan Väst (5)
Röda Korsets Högskola (5)
Högskolan Kristianstad (3)
Högskolan i Gävle (3)
Karlstads universitet (2)
Ersta Sköndal Bräcke högskola (2)
Mälardalens högskola (1)
Blekinge Tekniska Högskola (1)
Sophiahemmet Högskola (1)
visa färre...
Språk
Engelska (3536)
Svenska (44)
Isländska (3)
Danska (2)
Spanska (2)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (3587)
Naturvetenskap (76)
Samhällsvetenskap (57)
Teknik (15)
Lantbruksvetenskap (5)
Humaniora (4)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy